Ray Sandip, Britschgi Markus, Herbert Charles, Takeda-Uchimura Yoshiko, Boxer Adam, Blennow Kaj, Friedman Leah F, Galasko Douglas R, Jutel Marek, Karydas Anna, Kaye Jeffrey A, Leszek Jerzy, Miller Bruce L, Minthon Lennart, Quinn Joseph F, Rabinovici Gil D, Robinson William H, Sabbagh Marwan N, So Yuen T, Sparks D Larry, Tabaton Massimo, Tinklenberg Jared, Yesavage Jerome A, Tibshirani Robert, Wyss-Coray Tony
Satoris, Inc., 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA.
Nat Med. 2007 Nov;13(11):1359-62. doi: 10.1038/nm1653. Epub 2007 Oct 14.
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.
一种针对阿尔茨海默病的分子检测可能会带来更好的治疗方法。我们在血浆中发现了18种信号蛋白，这些蛋白可用于对来自阿尔茨海默病患者和对照受试者的盲样进行分类，准确率接近90%，还能识别出在2至6年后从轻度认知障碍发展为阿尔茨海默病的患者。对这18种蛋白质的生物学分析表明，在症状前的阿尔茨海默病中，造血、免疫反应、细胞凋亡和神经元支持存在系统性失调。
